Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.69 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.57 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469158 | 0.84 | MAOB (0.82) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL7246097 | 0.84 | MAOB (0.46) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL4404036 | 0.82 | MAOB (1.00) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL16795623 | 0.80 | MAOB (0.65) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL23004576 | 0.79 | MAOB (0.69) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL863891 | 0.79 | MAOB (0.66) | MAOBPARP10MAOAIDO1AGXT | |
| SCHEMBL16795800 | 0.79 | MAOB (0.69) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL695070 | 0.79 | MAOB (0.66) | MAOBMAOAIDO1AGXT | |
| SCHEMBL22290667 | 0.79 | MAOB (0.69) | MAOBPARP15PARP10PARP14MAOA | |
| SCHEMBL8306880 | 0.79 | MAOB (0.71) | MAOBPARP15PARP10PARP14MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671825-B | Synthesis method of chiral 4H-3, 1-benzoxazine compound containing selenoaryl | 安徽泽升科技有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513262-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-08-20 | — | — | US | disclosed |
| CN-102712610-A | Novel 3-hydroxy-5-arylisothiazole derivatives | MOCHIDA PHARM CO LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-6727256-B1 | 4-AMINOQUINAZOLINE DERIVATIVES AS ANTICARCINOGENIC AGENTS | SMITHKLINE BEECHAM CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6713485-B2 | ANTIPROLIFERATIVE AGENTS; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| EP-1294715-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| WO-2002002552-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | CCNH, HRH2, HRH1 | MAOB 110/4885PARP15 1616/4885PARP10 2078/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | MAOB 945/4885PARP15 689/4885PARP10 1439/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885PARP15 2502/4885PARP10 2597/4885 |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ABL1, ERBB2, CDK2 | MAOB 327/4885PARP15 1591/4885PARP10 1795/4885 |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | ABL1, ERBB2, SRC | MAOB 617/4885PARP15 2502/4885PARP10 2597/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885PARP15 2502/4885PARP10 2597/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | MAOB 617/4885PARP15 2502/4885PARP10 2597/4885 |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | ERBB4, ABL1, ERBB2 | MAOB 3698/4885PARP15 1731/4885PARP10 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.